



A Schonenberger

Contact

A Schonenberger

Publications (3)

Zaman K, Aebi S, Brauchli P, Genton C, Berthod G, Giobbie-Hurder A, Simcock M, Lüthi J, Pagani O, Schonenberger A, Huober J, Thürlimann B, on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). *Ann Oncol* 2011

Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober J, Spirig C, Lerch S, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). *Ann Oncol* 2010; 22:80-5.

Hess D, Ribi K, Ballabeni P, Schuller J, Rauch D, Rochlitz C, Mattmann S, Schonenberger A, Pagani O, Thürlimann B, Köberle D, Swiss Group for Clinical Cancer Research. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). *Oncology* 2007; 73:228-37.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch